Journal of Pharmacology and Pharmacotherapeutics

RESEARCH ARTICLE
Year
: 2021  |  Volume : 12  |  Issue : 2  |  Page : 37--41

Is a glucocorticoid antagonist a potential treatment alternative for antipsychotic-induced weight gain?


Wisam Al Jumaili1, Chintan Trivedi2, Kaushal Shah3, Mahwish Adnan4, Zeeshan Mansuri5, Shailesh Jain6 
1 Northwest Clinical Research Center, Bellevue, Washington, USA
2 St. David Medical Center, Austin, TX, USA
3 Department of Psychiatry, Griffin Memorial Hospital, Norman, and Oklahoma State University, Tulsa, Oklahoma, USA
4 Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
5 Department of Psychiatry, Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, USA
6 Department of Psychiatry, Texas Tech University Health Science Center at Odessa/Permian Basin, Odessa, Texas, USA

Correspondence Address:
Wisam Al Jumaili
Department of Psychiatry/Northwest Clinical Research Center 1951, 152nd Place NE Suite 200, Bellevue - 98007, Washington
USA

Objective: To evaluate the efficacy and safety of mifepristone as a new treatment modality for antipsychotic-induced weight gain. Methods: We searched databases up to March 2021, for the published English-language literature including a Medical Subject Heading “Mifepristone,” “Receptors, Glucocorticoid,” “Weight gain,” “Overweight,” “Obesity,” “Body Weight Change,” “Antipsychotics Agents,” “Glucocorticoid Receptor Blocker,” “Glucocorticoid Receptor antagonist.” We identified two clinical and four preclinical studies utilizing mifepristone as a treatment modality. Results: The results of the olanzapine clinical trial showed that mean increase in weight from baseline to day 14 was greater in the olanzapine with the placebo group (3.2 ± 0.9 kg) than the olanzapine with mifepristone group (2.0 ± 1.2 kg) and the mifepristone with placebo (2.0 ± 0.7 kg), and a similar effect was observed in the risperidone with mifepristone clinical trial. Conclusions: Mifepristone shows potential in the management of AIWG. Glucocorticoid antagonists can be a viable alternative to curb this side effect. Large-scale clinical studies are warranted to determine the medication's safety and efficacy based on this mechanism of action.


How to cite this article:
Al Jumaili W, Trivedi C, Shah K, Adnan M, Mansuri Z, Jain S. Is a glucocorticoid antagonist a potential treatment alternative for antipsychotic-induced weight gain?.J Pharmacol Pharmacother 2021;12:37-41


How to cite this URL:
Al Jumaili W, Trivedi C, Shah K, Adnan M, Mansuri Z, Jain S. Is a glucocorticoid antagonist a potential treatment alternative for antipsychotic-induced weight gain?. J Pharmacol Pharmacother [serial online] 2021 [cited 2021 Oct 18 ];12:37-41
Available from: http://www.jpharmacol.com/article.asp?issn=0976-500X;year=2021;volume=12;issue=2;spage=37;epage=41;aulast=Al;type=0